Erythropoietin (EPO) was originally described as a regulator of erythropoiesis. Recently, synthesis of EPO and expression of the EPO receptor (EPO-R) have been reported for the central nervous system (CNS). The potential use of EPO to prevent or reduce CNS injury and the paucity of information regarding its entry into the human CNS led us to examine the pharmacokinetics (PK) of recombinant human EPO (r-HuEPO) in the serum and cerebrospinal fluid (CSF).
Hematology Division, Rm 2760, London Health Sciences Centre/University of Western Ontario, LHSC, Westminster Site, 800 Commissioners Road East, London, ON, N6A 4G5, Canada. anargyros.xenocostas@lhsc.on.ca
